



FORM PTO-1449 	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,036
		APPLICANT Mitchell, et al.	
		FILING DATE September 25, 2003	GROUP 1624

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
D, K.	1	5,445,829	08/1995	Paradissis, et al.			
	2	5,565,561	10/1996	Müller, et al.			
	3	5,576,012	11/1996	Baver, et al.			
	4	5,601,845	02/1997	Buxton, et al.			
	5	5,641,515	06/1997	Ramtoola			
	6	5,653,987	08/1997	Modi, et al.			
	7	5,654,286	08/1997	Hostetler			
	8	5,667,809	09/1997	Trevino, et al.			
	9	5,683,676	11/1997	Akehurst, et al.			
	10	5,688,529	11/1997	Lidgate, et al.			
	11	5,707,615	01/1998	Cardin, et al.			
	12	5,707,641	01/1998	Gertner, et al.			
	13	5,726,181	03/1998	Hausheer, et al.			
	14	5,733,888	03/1998	Carver, et al.			
	15	5,874,443	02/1999	Kiely, et al.			
	16	5,886,210	03/1999	Rayle, et al.			
	17	5,922,683	11/1999	Sigl			
	18	6,350,759	02/2002	Casara, et al.			
	19	6,500,825	12/2002	Lan, et al.			
↓	20	6,506,787	01/2003	Fujishita, et al.			
↓	21	6,509,331	01/2003	Audia, et al.			

EXAMINER	<i>Dunck Hoff</i>	DATE CONSIDERED	5/26/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

 <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (USE SEVERAL SHEETS IF NECESSARY)</p>	ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,036
	APPLICANT Mitchell, et al.	
	FILING DATE September 25, 2003	GROUP 1624

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
B.K.	<p>22 Faulkner, D. John, "Marine Pharmacology", <i>Antonie van Leeuwnhoek</i>, Vol. 77, pp. 135-145 (2000).</p>
	<p>23 Fenical, William, et al., "Marine Microorganisms as a Developing Resource for Drug Discovery", <i>Pharmaceutical News</i>, Vol. 9, pp. 489-494 (2002).</p>
	<p>24 Gerber, Nancy N., "A New Prodiginine (Prodigiosin-like) Pigment from Streptomyces. Antimalarial Activity of Several Prodiginines", <i>The Journal of Antibiotics</i>, Vol. XXVIII, No. 3, pp. 194-199 (Mar., 1975).</p>
	<p>25 Kojiri, Katsuhisa, et al., "A New Macroyclic Lactam Antibiotic, VE-14106, I. Taxonomy, Isolation, Biological Activity and Structural Elucidation", <i>The Journal of Antibiotics</i>, Vol. 45, No. 6, pp. 868-874 (June, 1992).</p>
	<p>26 Okami, Yoshiro, "The Search for Bioactive Metabolites from Marine Bacteria", <i>The Journal of Marine Biotechnology</i>, Vol 1, pp. 59-65 (1993).</p>
	<p>27 Shindo, Kazutoshi, et al., "Vicenistatin, a Novel 20-Membered Macroyclic Lactam Antitumor Antibiotic", <i>The Journal of Antibiotics</i>, Vol. 46, No. 7, pp. 1076-1081.</p>
	<p>28 Takahashi, I., et al., "Communication to the Editor", <i>The Journal of Antibiotics</i>, Vol. 50, No. 2, 186-188</p>
↓	<p>29 Wasserman, Harry H., et al., <i>Journal of the American Chemical Society</i>; Vol. 91, No. 5, pp. 1263-1264 (Feb., 1969).</p>

S:\DOCS\MTMMTM-5633.DOC  
012304

EXAMINER <i>Bruce Kiff</i>	DATE CONSIDERED <i>5/26/05</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

 <p>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>	<p>ATTY. DOCKET NO. NEREUS.069A</p>	<p>APPLICATION NO. 10/873,036</p>
	<p>APPLICANT Mitchell, et al.</p>	
	<p>FILING DATE September 25, 2003</p>	<p>GROUP Unknown</p>

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**EXAMINER  
INITIAL**

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

- D.K. 3. Arai, et al. "Absolute Stereochemistry of Vicenistatin, a Novel 20-Membered Macrocyclic Lactam Antitumor Antibiotic." Tetrahedron Letters. 39: 3181-3184 (1998).

B.K. International Search Report for International Application No. PCT/US 03/30518 dated 5/25/04

S:\DOCS\MTM\MTM-6572.DOC sma072204

EXAMINER	<i>Bruce Ziff</i>	DATE CONSIDERED	<i>5/26/05</i>
----------	-------------------	-----------------	----------------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 809; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 <i>O P T E S C I E S</i> SEP 15 2004 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NEREUS.069A	APPLICATION NO. 10/673,036
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
APPLICANT Mitchell, et al.		
FILING DATE September 25, 2003	GROUP 1624	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
B.K.	1	Alm, et al. "Effects of topically Applied PGF <sub>2α</sub> and its Isopropylester on Normal and Glaucomatous Human Eyes." <i>Prog. Clin. Biol. Res.</i> 312: 447-58 (1998).
B.K.	2	"Bioreversible Carriers in Drug Design: Theory and Application," edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987).
B.K.	3	Fenical, William. "Chemical Studies of Marine Bacteria: Developing a New Resource." <i>Chem. Rev.</i> 93:1673-1683 (1993).
B.K.	4	Fingl, et al. Basis of Therapeutics. 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 13. "Drugs Effective in the Therapy of the Epilepsies," (1975).
B.K.	5	Fingl, et al. Basis of Therapeutics. 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 17. "Analgesic-Antipyretics, Anti-Inflammatory Agents, and Drugs Employed in the Therapy of Gout," (1975).
B.K.	6	Fingl, Edward. Basis of Therapeutics. 5 <sup>th</sup> Edition. Macmillan Publishing Co. Chp. 49. "Laxatives and Cathartics," (1975).
B.K.	7	Higuchi, et al. "Pro-drugs as Novel Delivery Systems." A.C.S. Symposium Series, American Chemical Society. 14(3): 154-183 (1975).
B.K.	8	Joshi, A. "Microparticulates for Ophthalmic Drug Delivery." <i>J. Ocul. Pharmacol.</i> , 10(1):29-45 (1994).
	9	Khokhlova, et al. "A Chemical Study of the Major Vitamycin Component." Institute of Microbiology, Academy of Sciences of the USSR, Moscow, pgs. 841-845, Russian (1964).
	10	Krasilnikov, et al. "A New Species in the Group of <i>Actinomyces Aurantiacus</i> ," pgs. 482-489 (1960).
B.K.	11	Mayer et al. "Efficacy of a Novel Hydrogel Formulation in Human Volunteers." <i>Ophthalmologica</i> . 210(2):101-3 (1996).
B.K.	12	Mordenti, et al. "Intraocular Pharmacokinetics and Safety of a Humanized Monoclonal Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation." <i>Toxicol. Sci.</i> 52(1):101-6 (1999).
B.K.	13	Shedden, et al. "Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double-Masked, Multicenter Study." <i>Clin. Ther.</i> , 23(3): 440-50 (2001).

S:\DOCS\MTM\MTM-6823.DOC sma090204

EXAMINER	<i>Bruce Kipp</i>	DATE CONSIDERED	5/26/05
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			